1-2 of 2
David J. Collins
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer

Paul Nathan, Martin Zweifel, Anwar R. Padhani, Dow-Mu Koh, Matthew Ng, David J. Collins, Adrian Harris, Craig Carden, Jon Smythe, Nita Fisher, N. Jane Taylor, J. James Stirling, Shiao-Ping Lu, Martin O. Leach, Gordon J.S. Rustin, Ian Judson
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (12): 3428–3439.
https://doi.org/10.1158/1078-0432.CCR-11-3376
Published: 14 June 2012
View article titled, Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer
Open the PDF for Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer in another window
Journal Articles

Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

Mei-Lin W. Ah-See, Andreas Makris, N. Jane Taylor, Mark Harrison, Paul I. Richman, Russell J. Burcombe, J. James Stirling, James A. d'Arcy, David J. Collins, Michael R. Pittam, Duraisamy Ravichandran, Anwar R. Padhani
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (20): 6580–6589.
https://doi.org/10.1158/1078-0432.CCR-07-4310
Published: 16 October 2008
View article titled, Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Open the PDF for Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast Cancer in another window